CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up.
An article joins this feed when it matches these terms. Each one is also a search of its own.
Mankind to invest EUR 48 million for 70% stake in Armed Cell Therapeutics Armed Cell Therapeutics (ACTx) has a pipeline of next-generation CAR-T assets, with lead programs in non-Hodgkin lymphoma and small cell lung cancer ACTx will pursue innovative means of CAR…
Bioengineer.org
Danish researchers report that low-level skipping of CD19 exon 2, detectable in pre-treatment RNA-sequencing data, correlates with relapse after anti-CD19 CAR-T therapy and may serve as a future biomarker.
Decatur Daily NEW YORK â Matt Walker couldn't pet a dog without sneezing â until he and other scientists used a gene editing technique to produce a hypoallergenic beagle named Bailey à This page requires Javascript Javascript is…
The virus used to deliver healing DNA in gene therapy is under renewed scrutiny. In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to…
A systematic review and meta-analysis of 23 studies and 547 patients finds that CD19-directed CAR T-cell therapy delivers encouraging one-year survival and complete response rates in relapsed or refractory primary and secondary CNS lymphoma, with a manageable toxicity profile. Subject of Research:…
Home / News / Grants and Awards / Genetics The University of Miami geneticist is recognized for disease-gene discoveries that have improved the diagnosis of inherited neuropathies and identified potential targets for treatment. Stephan Züchner, M.D., Ph.D., professor of human genetics…
Researchers used a vector-free CRISPR activation system to boost dopamine biosynthesis genes in cellular models of Parkinsonian neurotoxicity, finding modest DDC upregulation, no GCH1 activation, and no added toxicity.
The faculty discuss a recent exchange in Nature Reviews Clinical Oncology on the role of CAR T-cell therapy and where it fits in the treatment sequence, including concerns about toxicity and how recognition and management of these toxicities have evolved.
The Pharma Letter